This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Queen's University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $749,700
Vancomycin dosing for serious MRSA infections: A non-inferiority randomized trial of trough level versus AUC/MIC.
CIHR · 2024 · Principal investigator
Vancomycin dosing for serious MRSA infections: A non-inferiority randomized trial of trough level versus AUC/MIC.
Principal investigators: Bai, Anthony D; Daneman, Nick; Jorgensen, Sarah C; Lee, Todd C; Loeb, Mark B; McDonald, Emily G; Mertz, Dominik; Morris, Andrew M
Keywords: Antibiotic Resistance; Antibiotic Therapy; Methicillin-Susceptible Staphylococcus Aureus (Mrsa); Vancomycin
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.